Drug intelligence / Profile preview

Xiangqin Jiere Granules

Development stage: Phase 2
Lead developer: Yunnan Fangsheng Ronghe Pharmaceutical
Administration: Oral

Overview

Xiangqin Jiere Granules (香芩解热颗粒) is an innovative Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical. Formulated as oral granules, it is primarily indicated for the treatment of fever and symptoms associated with respiratory diseases, such as the common cold or influenza. The formulation is designed to clear heat and resolve toxins according to TCM principles. As of the latest clinical development updates, the drug has been approved for clinical trials and is currently in Phase 3 research in China, positioning it as a late-stage candidate in the company's respiratory pipeline.

Brand names: 香芩解热颗粒
Other names: Xiangqin Jiere GranulesXiangqin Jiere Keli香芩解热颗粒

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Xiangqin Jiere Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiangqin Jiere Granules.